Abbonarsi

Consumers appropriately self-treat based on labeling for over-the-counter hydrocortisone - 21/08/11

Doi : 10.1016/j.jaad.2005.01.107 
Charles N. Ellis, MD a, , Janine L. Pillitteri, PhD b, Theodore K. Kyle, RPh c, Michelle D. Ertischek, BA d, Steven L. Burton, MBA c, Saul Shiffman, PhD d
a From the Department of Dermatology, University of Michigan Medical School, Ann Arbor 
b Pinney Associates, Seattle 
d Bethesda 
c GlaxoSmithKline Consumer Healthcare, Pittsburgh 

Correspondence and reprint requests: Charles N. Ellis, MD, Department of Dermatology, University of Michigan Medical School, 1500 E Medical Center Dr, Ann Arbor, MI 48109-0314.

Ann Arbor, Michigan; Seattle, Washington; Pittsburgh, Pennsylvania; and Bethesda, Maryland

Abstract

Background

Over-the-counter (OTC) topical corticosteroids, such as hydrocortisone cream (HC), are commonly used for the treatment of minor dermatological conditions. The safety and efficacy of such products are well documented, but details on patterns of use and self-treatment with HC in the OTC environment remain scarce.

Objective

We sought to determine compliance with label directions of OTC HCs by examining self-reported patterns of OTC HC use in adults and children.

Methods

A random digit-dialed telephone survey was conducted with 2000 US adults. Following identification of users of OTC HC in the last 6 months, respondents were asked questions about the conditions being treated with OTC HC and the frequency and duration of use in both adults and children.

Results

Of adults completing the survey, 20% (n=396) had used OTC HC. In 83% of cases, the conditions treated were consistent with the OTC label. Use was limited; HC was applied ≤4 times daily in 98% of adult users and lasted ≤7 days in 92%. Patterns of pediatric use were similar and almost always consistent with the labeling. Of households with children, 25% (n=168) had used OTC HC to treat pediatric dermatological conditions. Of child users, 93% were 2 years of age or older, treatment was limited (97% applied HC ≤4 times daily and 94% of treatments lasted ≤7 days), and the conditions treated were appropriate in 86% of cases.

Limitations

This telephone survey relied on respondents' recall and self-reporting. Our data on pediatric use of OTC HC are skewed toward treatment of younger children.

Conclusion

The data suggest that OTC HC products are used for self-treatment in a limited and appropriate fashion that is likely to be safe in both adults and children.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Supported by GlaxoSmithKline Consumer Healthcare.
Disclosure: Drs Ellis, Pillitteri, and Shiffman and Ms. Ertischek serve as consultants to GlaxoSmithKline Consumer Healthcare; Dr Ellis also serves as a consultant to other manufacturers of topical corticosteroids. Mr. Burton and Mr. Kyle are employed by GlaxoSmithKline Consumer Healthcare.


© 2005  American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 53 - N° 1

P. 41-51 - luglio 2005 Ritorno al numero
Articolo precedente Articolo precedente
  • American Board of Dermatology examination dates
| Articolo seguente Articolo seguente
  • Psoriasis herpeticum: Three cases of Kaposi's varicelliform eruption in psoriasis
  • Beth R. Santmyire-Rosenberger, Thomas P. Nigra

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.